PD52 - PD52: Prostate Cancer: Markers II

Podium Presenter(s)

• 

  Rohann Correa, MD, PhD

  Western University

  PDF Slides
• MF

  Mikolaj Filon, BS

  UWSMPH

  PDF Slides and Audio
• 

  Andrew Gusev

  University of Massachusetts Medical School

  PDF Slides and Audio
• BH

  Brian Helfand
• HK

  Howard Korman
• OK

  Ohad Kott

  PDF Slides
• PL

  Patrick Leo

  Case Western Reserve University

  PDF Slides and Audio
• HL

  Hans Lilja, MD, PhD
• 

  Yaw Nyame, MD, MBA

  University of Washington
• 

  Justin Shaya, MD

  UC San Diego Moores Cancer Center

  PDF Slides and Audio
• 

  Joseph Wagner, MD

  Hartford HealthCare/University of Connecticut

  PDF Slides and Audio
• 

  Tohru Yoneyama, PhD

  Hirosaki University Graduate school of medicine

  PDF Slides and Audio

Presentations:

• 7:00 AM – 9:00 AM

  PD52-01: A Deep Learning Algorithm for the Diagnosis and Gleason Grading of Whole Slide Images of Prostate Cancer Core Biopsies
  Ohad Kott
• 7:00 AM – 9:00 AM

  PD52-02: Computer-Extracted Features of Gland Morphology from Digital Tissue Images is Comparable to Decipher for Prognosis of Biochemical Recurrence Risk Post-Surgery
  Patrick Leo – Case Western Reserve University
• 7:00 AM – 9:00 AM

  PD52-03: Multi-parametric magnetic resonance imaging of multi-focal prostate cancer unmasks intra-prostatic genomic heterogeneity and novel radio-genomic correlates: results of the Smarter Prostate Interventions and Therapeutics (SPIRIT) study
  Rohann Correa, MD, PhD – London Health Sciences Centre
• 7:00 AM – 9:00 AM

  PD52-04: Rare Germline Pathogenic Mutations of DNA Repair Genes Are Most strongly Associated with Grade Group 5 Prostate Cancer
  Brian Helfand
• 7:00 AM – 9:00 AM

  PD52-05: Assessing PAM50 Molecular Subtypes by Race and Outcomes in Men with Localized Prostate Cancer
  Yaw A. Nyame, MD, MBA
• 7:00 AM – 9:00 AM

  PD52-06: Computational Immunogenomic Modeling of Immunoevasive Aggressive Prostate Cancer
  Howard Korman
• 7:00 AM – 9:00 AM

  PD52-07: Tandem Histone Methyltransferase Upregulation Defines a Unique Aggressive Prostate Cancer Phenotype
  Mikolaj Filon, BS
• 7:00 AM – 9:00 AM

  PD52-08: Changes in blood levels of prostate kallikrein-related and microseminoprotein-beta marker levels following 5ARI therapy: data from 500 PCPT-participants.
  Hans Lilja, MD, PhD
• 7:00 AM – 9:00 AM

  PD52-09: Development of a Urinary Metabolomic Signature for Prostate Cancer Using Capillary Electrophoresis Mass Spectrometry
  Andrew Gusev
• 7:00 AM – 9:00 AM

  PD52-10: Clinical significance of the LacdiNAc-glycosylated Prostate-Specific Antigen Assay for prostate cancer detection
  Tohru Yoneyama, PhD – Dept. of Advanced transplantation and Regenerative Med. Hirosaki University
• 7:00 AM – 9:00 AM

  PD52-11: Unique genomic signature to predict biochemical recurrence following radical prostatectomy
  Joseph Robert Wagner, MD – Hartford HealthCare
• 7:00 AM – 9:00 AM

  PD52-12: Analysis of the prognostic significance of circulating tumor DNA (ctDNA) in metastatic castrate resistant prostate cancer (mCRPC)
  Justin Arshed Shaya, MD